← 返回

γδ T 细胞:癌症免疫细胞治疗中的变革者

英文原题:γδ T Cells: Game Changers in Immune Cell Therapy for Cancer.

查看英文原题

γδ T Cells: Game Changers in Immune Cell Therapy for Cancer.

PubMed 2025/03/21(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

γδ T 细胞是 T 淋巴细胞中一个独特的亚群,具有使其成为极具前景的癌症治疗候选者的显著特征。其不依赖 MHC 识别肿瘤抗原、介导直接细胞毒作用的能力以及在调节肿瘤微环境中的作用,使其成为癌症免疫治疗中的多功能工具。本综述整合并综合了关于 γδ T 细胞的现有数据,重点在于体外扩增方案的开发与优化。详细阐述了关键方面,如激活策略、共培养系统、细胞因子使用及其他参数,以确保稳健的细胞增殖和功能,这可能对开发或优化临床实践的人员具有价值。最后,我们讨论了 γδ T 细胞研究的当前进展、临床经验,并强调了需要进一步探索的领域。基于这些数据,我们假设并提出了潜在的新应用,例如工程化 γδ T 细胞以增强对免疫检查点通路的抵抗,或在肿瘤微环境内实现局部细胞因子递送,这可能拓宽其在癌症及其他疾病治疗中的治疗影响。

展开英文摘要原文

Gamma delta (γδ) T cells are a unique subset of T lymphocytes with distinctive features that make them highly promising candidates for cancer therapy. Their MHC-independent recognition of tumor antigens, ability to mediate direct cytotoxicity, and role in modulating the tumor microenvironment position them as versatile agents in cancer immunotherapy.

This review integrates and synthesizes the existing data on γδ T cells, with an emphasis on the development and optimization of in vitro expansion protocols. Critical aspects are detailed such as activation strategies, co-culture systems, cytokine use, and other parameters to ensure robust cell proliferation and functionality, which may be valuable for those developing or optimizing clinical practices.

Finally, we discuss current advancements in γδ T cell research, clinical experience, and highlight areas needing further exploration. Considering these data, we hypothesize and propose potential new applications such as engineering γδ T cells for enhanced resistance to immune checkpoint pathways or for localized cytokine delivery within the tumor microenvironment, which could broaden their therapeutic impact in the treatment of cancer and beyond.

论文信息

作者
Subhi-Issa N、Tovar Manzano D、Pereiro Rodriguez A、Sanchez Ramon S、Perez Segura P、Ocaña A
第一作者单位
Department of Immunology, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.Spain
通讯作者单位
Department of Oncology, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.Spain
文献类型
综述
期刊
Cancers2025 Mar 21
原文标识
PubMed 40227601 · DOI 10.3390/cancers17071063